{"id":"menjugate","safety":{"commonSideEffects":[{"rate":"10-50","effect":"Injection site reactions (pain, redness, swelling)"},{"rate":"5-15","effect":"Fever"},{"rate":"5-10","effect":"Irritability"},{"rate":"5-10","effect":"Drowsiness"},{"rate":"5-10","effect":"Loss of appetite"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine consists of meningococcal serogroup C polysaccharide conjugated to a protein carrier (tetanus toxoid), which enhances immunogenicity and T-cell dependent immune response. This conjugation allows the vaccine to elicit both IgG antibodies and immunological memory, providing protection against invasive meningococcal disease caused by Neisseria meningitidis serogroup C.","oneSentence":"Menjugate is a meningococcal conjugate vaccine that stimulates the immune system to produce antibodies against serogroup C meningococcal polysaccharide capsule.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:54:25.774Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroup C in infants, children, adolescents, and adults"}]},"trialDetails":[{"nctId":"NCT06165276","phase":"PHASE1","title":"A Phase I, Randomized, Modified Single-blind, Active-controlled (Infants Only), Four-stage, Step-down, Comparative, Multi-center Study","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2006-07-25","conditions":"Meningococcal Immunization","enrollment":285},{"nctId":"NCT02955797","phase":"PHASE3","title":"Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Toddlers","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2017-02-24","conditions":"Meningitis, Meningococcal Meningitis, Meningococcal Infections","enrollment":918},{"nctId":"NCT01144663","phase":"PHASE3","title":"Immunogenicity and Safety of Meningococcal Vaccine GSK 134612 Co-administered With Pneumococcal and DTPa-HBV-IPV/Hib Vaccines","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-07-01","conditions":"Infections, Meningococcal, Meningococcal Vaccines","enrollment":2095},{"nctId":"NCT01171989","phase":"PHASE2","title":"Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine Administered as a Booster Dose","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-08-18","conditions":"Tetanus, Diphtheria, Haemophilus Influenzae Type b","enrollment":391},{"nctId":"NCT00970307","phase":"PHASE2","title":"Immunogenicity and Safety Study of GSK Biologicals' GSK2202083A Vaccine in Healthy Infants at 2, 3 and 4 Months of Age","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-08-13","conditions":"Tetanus, Diphtheria, Haemophilus Influenzae Type b","enrollment":421},{"nctId":"NCT00674583","phase":"PHASE3","title":"Comparison of GSK Biologicals' Meningococcal Vaccine (GSK134612) and Licensed MenC-CRM197 Vaccine in Healthy Children","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-05-09","conditions":"Infections, Meningococcal","enrollment":414},{"nctId":"NCT01098474","phase":"PHASE2","title":"Safety and Immunogenicity Study of a Candidate Tuberculosis Vaccine in Healthy Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-07-07","conditions":"Tuberculosis","enrollment":301},{"nctId":"NCT01553279","phase":"PHASE3","title":"Immunogenicity and Safety of V419 (PR51) in Combination With MCC in Infants and Toddlers (V419-011)","status":"COMPLETED","sponsor":"MCM Vaccines B.V.","startDate":"2012-03-30","conditions":"Neisseria Meningitidis, Bacterial Infections, Virus Diseases","enrollment":284},{"nctId":"NCT00127855","phase":"PHASE2","title":"Dose Ranging Study of Combined Haemophilus Influenzae Type B-Meningococcal Serogroups CY (Hib-MenCY-TT) Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2003-03-01","conditions":"Haemophilus Influenzae Type b, Neisseria Meningitidis","enrollment":409},{"nctId":"NCT00129116","phase":"PHASE2","title":"3 Formulations of Hib-MenCY-TT Vaccine & 1 Formulation of Hib-MenC-TT Vaccine Compared to Licensed Meningococcal Serogroup C Conjugate Vaccine, Each Administered at 2,3,4 Mths of Age","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2003-03-01","conditions":"Haemophilus Influenzae Type b, Neisseria Meningitidis","enrollment":388},{"nctId":"NCT01090453","phase":"PHASE2","title":"Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine in Healthy Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-05-17","conditions":"Tetanus, Hepatitis B, Haemophilus Influenzae Type b","enrollment":480},{"nctId":"NCT00871741","phase":"PHASE2","title":"Feasibility Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine in Healthy Infants at 3, 5 and 11 Months of Age.","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2009-04-01","conditions":"Tetanus, Poliomyelitis, Neisseria Meningitidis","enrollment":16},{"nctId":"NCT01359449","phase":"PHASE3","title":"Study of Two Doses of Menactra® or One Dose of Monovalent Meningococcal Group C Vaccine With Routine Immunizations","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2011-05","conditions":"Meningitis, Meningococcal Infection","enrollment":123},{"nctId":"NCT01889836","phase":"PHASE1","title":"Safety and Immunogenicity Study in Young Adults the Meningococcal Serogroup C Vaccine Produced by Bio-Manguinhos","status":"COMPLETED","sponsor":"The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)","startDate":"2014-05","conditions":"Meningitis, Meningococcal, Serogroup C","enrollment":60},{"nctId":"NCT00262015","phase":"PHASE4","title":"Kinetic of Immune Memory Response After Re-Vaccination With Meningococcal Vaccine","status":"UNKNOWN","sponsor":"Chiron Corporation","startDate":"2003-09","conditions":"Meningococcal Disease; Meningococcal Meningitis","enrollment":264}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":13,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["MenC-CRM197vaccine","MenC-CRM","Novartis' meningococcal serogroup C CRM197 protein conjugated vaccine."],"phase":"marketed","status":"active","brandName":"Menjugate®","genericName":"Menjugate®","companyName":"GlaxoSmithKline","companyId":"glaxosmithkline","modality":"Biologic","firstApprovalDate":"","aiSummary":"Menjugate is a meningococcal conjugate vaccine that stimulates the immune system to produce antibodies against serogroup C meningococcal polysaccharide capsule. Used for Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroup C.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":3,"withResults":3},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}